Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04806035
Title Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc
Indications

non-Hodgkin lymphoma

chronic lymphocytic leukemia

Therapies

TG-1801 + Ublituximab

TG-1801

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
TG Therapeutics Investigational Trial Site Recruiting Fayetteville Arkansas 72703 United States Details
TG Therapeutics Investigational Trial Site Recruiting Hackensack New Jersey 07601 United States Details
TG Therapeutics Investigational Trial Site Recruiting Chattanooga Tennessee 37404 United States Details
TG Therapeutics Investigational Trial Site Recruiting Nashville Tennessee 37203 United States Details
TG Therapeutics Investigational Trial Site Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field